Myotonic Dystrophy Type 1: Unlocking Better Outcomes Through Standardized Measures
"Experts worldwide collaborate to refine disease assessment, paving the way for effective treatments and improved quality of life."
Myotonic dystrophy type 1 (DM1) presents a complex and varied challenge. Its impact extends beyond muscle weakness, affecting cognition, cardiac function, sleep, and overall well-being. Recognizing this complexity, researchers and clinicians across the globe are uniting to forge a path toward more effective treatments and improved quality of life for those living with DM1.
Central to this effort is the development and implementation of standardized outcome measures—tools used to assess the effectiveness of interventions in clinical trials and to monitor disease progression in clinical practice. However, the inherent variability of DM1 has made identifying and validating these measures a significant challenge. This article delves into the ongoing international effort to address this challenge, highlighting the progress made and the road ahead.
The Outcome Measures in Myotonic Dystrophy (OMMYD) initiative, inspired by the OMERACT methodology in rheumatology, is spearheading this drive. Through a series of international workshops, OMMYD brings together experts to establish a core set of reliable and meaningful outcome measures that capture the multifaceted nature of DM1.
DM1 Prevalence and Burden
A 2021 Myotonic report cites a DM1 prevalence of 4.76 per 10,000 births, or approximately 1 in every 2,100 births. The report states that this prevalence is significantly higher than previously recognized and highlights how often DM1 may be missed in diagnosis. An ISPOR 2026 systematic literature review and meta-analysis is examining DM1 prevalence across nine countries, including the United Kingdom, Italy, Spain, Germany, France, Canada, the United States, and Japan. A separate meta-analysis of 17 studies from Europe and Asia reported a pooled prevalence of 9.27 per 100,000 individuals, with estimates ranging from 0.37 to 36.29 per 100,000.
Why Standardized Measures Matter: The Key to Meaningful Progress in DM1
Imagine trying to compare the results of two different clinical trials for a new DM1 drug. If each trial used completely different methods to assess muscle strength, cognitive function, or fatigue, it would be nearly impossible to determine which treatment was truly more effective. This is where standardized outcome measures become crucial.
- Objective Comparisons: Allow researchers to directly compare results across different studies.
- Accelerated Progress: Facilitate the identification of effective treatments and interventions.
- Informed Clinical Decisions: Provide clinicians with reliable tools to monitor disease progression and tailor treatment plans.
- Regulatory Approval: Necessary to make drug labeling claims and regulatory approval.
Improving Outcome Measurement
Recent DM1 research has focused on accelerating trial readiness and selecting outcome measures that capture key disease manifestations. The Nine-Hole Peg Test (NHPT) is described as a validated and recommended outcome measure in DM1 studies, including natural history and intervention studies. Research on executive functions and daily functioning reports that many of the measures used have been widely employed in the DM1 population and recommended by the OMMYD-3 international workshop. These findings support the use of established, disease-relevant measures while newer assessment approaches are evaluated.
Gaps in Evidence and Care
Consensus-based care recommendations state that DM1's multisystemic nature has made it difficult to develop rigorous evidence-based guidance for every affected body system and symptom. The recommendations were created to improve and standardize care despite the lack of complete evidence across all areas. The Muscular Dystrophy Association describes myotonic dystrophy as affecting muscles and many other organs in the body. It also defines myotonia as an inability to relax muscles at will and describes muscular dystrophy as progressive muscle degeneration involving weakness and tissue shrinkage.
The Future of DM1 Research: A Collaborative Path Forward
The OMMYD initiative represents a significant step forward in the effort to improve outcomes for individuals with DM1. By fostering collaboration and driving the development of standardized outcome measures, this international effort is paving the way for more effective treatments, more informed clinical decisions, and ultimately, a better quality of life for those affected by this complex condition.
A Multisystem Clinical Profile
A systematic review and meta-analysis examined the cognitive profile of people with DM1. A 2025 report on two large European cohorts, the French DM-Scope and Swedish NMiS registries, describes DM1 as a multisystemic, serious, and progressive disease and examines clinical characteristics and mortality among genetically confirmed patients. A clinical and therapeutic review emphasizes significant phenotypic heterogeneity and discusses cardiac, respiratory, cognitive, and pediatric aspects of DM1. Together, these sources frame DM1 as a condition requiring clinical assessment across multiple domains rather than a muscle-only evaluation.
Expanding Treatment Development
An AFM-Telethon report states that 12 DM1 drug candidates were being evaluated in June 2026. The candidates use varied approaches, including antisense oligonucleotides, small interfering RNA, gene therapy, microRNA, and repurposed medicines such as metformin. This range of strategies indicates a strong development effort across several therapeutic mechanisms. The Lansis overview describes DM1, also called Steinert disease, as a progressive, autosomal dominant multisystemic neuromuscular disorder caused by an unstable CTG trinucleotide repeat expansion in the 3′ untranslated region of the DMPK gene.
Beyond Skeletal Muscle
DM1 is described as a complex, multisystemic neuromuscular disorder with multiple pathological phenotypes, disease severities, and ages of onset. Its effects extend beyond skeletal muscle to multiple organs and systems, creating significant challenges in clinical management. The source emphasizes that addressing DM1 requires a comprehensive approach rather than treatment focused only on individual symptoms. This broader disease profile reinforces the need for coordinated assessment and care across affected systems.
The journey is ongoing, with continued efforts focused on refining existing measures, exploring new tools, and ensuring that these measures are accessible and relevant to diverse populations. Future research will emphasize:
<ul> <li>Longitudinal studies to better understand disease progression.</li> <li>Development of measures specific to different DM1 phenotypes (congenital, childhood, adult-onset, etc.).</li> <li>Incorporating patient-reported outcomes to capture the individual experience of living with DM1.</li> <li>Harmonizing data collection and analysis across research centers worldwide.</li> </ul>